Lantern Pharma Shows Promise in Pediatric Brain Cancer Treatment
Lantern Pharma's experimental drug LP-184 demonstrates significant potential in treating atypical teratoid rhabdoid tumors (ATRT), a rare and aggressive pediatric brain cancer, with preclinical studies showing remarkable improvements in survival rates.
Lantern Pharma has reported promising preclinical results for LP-184, an experimental drug targeting atypical teratoid rhabdoid tumors (ATRT), a rare and aggressive form of pediatric brain cancer. Research presented at the Society for Neuro-Oncology's Pediatric Neuro-Oncology Conference revealed substantial improvements in survival rates across multiple mouse models.
In one experimental model, LP-184 demonstrated a remarkable 345% increase in median survival, extending from 20 to 89 days, with statistical significance (p<0.0001). The drug exhibited potent anti-tumor activity across different ATRT subtypes and showed high blood-brain barrier penetration, along with a favorable safety profile.
Currently, ATRT, driven by SMARCB1 gene inactivation, lacks effective low-toxicity treatments. Lantern Pharma's research represents a potential breakthrough in addressing this critical medical need. The company plans to launch a pediatric Phase I clinical trial in late 2025 or early 2026, following the completion of its ongoing adult trial and pending consortium approvals.
This development underscores the potential of targeted therapeutic approaches in treating complex pediatric cancers. By leveraging artificial intelligence and machine learning technologies, Lantern Pharma is advancing innovative oncology drug discovery, potentially offering hope to patients with limited treatment options.